Related Experiment Video
Updated: Jan 15, 2026
07:40
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
6.0K
Adalimumab versus Conventional Immunosuppression for Uveitis (ADVISE) Trial
Douglas A Jabs, Elizabeth A Sugar1, Alyce E Burke2
1Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Ophthalmology
|October 12, 2025
Summary
Adalimumab demonstrated superior corticosteroid sparing at 6 months and discontinuation at 12 months for noninfectious uveitis compared to conventional immunosuppressants. This offers a promising treatment option for managing ocular inflammation.
Area of Science:
- Ophthalmology
- Immunology
Background:
- Noninfectious intermediate, posterior, or panuveitis often requires oral corticosteroids and immunosuppressants.
- Treatment goals include inflammation control and reducing corticosteroid dosage (corticosteroid sparing).
- Adalimumab, an anti-tumor necrosis factor agent, is used, but its comparative effectiveness is unclear.
Purpose of the Study:
- To compare the effectiveness of adalimumab versus conventional immunosuppressive drugs for noninfectious uveitis.
Main Methods:
- A randomized, unmasked, comparative effectiveness trial was conducted.
- Participants with active noninfectious intermediate, posterior, or panuveitis requiring immunosuppression were included.
- Adalimumab was compared against conventional immunosuppressive drugs (antimetabolites, calcineurin inhibitors, or both).
Main Results:
- Successful corticosteroid sparing at 6 months was higher with adalimumab (69%) versus conventional therapy (54%).
- Successful corticosteroid discontinuation at 12 months was also higher with adalimumab (55%) versus conventional therapy (40%).
- Adalimumab showed a statistically significant improvement in corticosteroid sparing at 6 months and discontinuation at 12 months.
Conclusions:
- Adalimumab treatment led to greater successful corticosteroid sparing and discontinuation compared to antimetabolites or calcineurin inhibitors.
- This suggests adalimumab is an effective option for managing noninfectious uveitis.
- The findings support adalimumab as a valuable therapeutic choice for patients with these conditions.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
488
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
488
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
434
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
434
01:27Open Angle Glaucoma: Treatment
961
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
961
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
490
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
490
01:29Drugs for Treatment of Ulcerative Colitis in IBD
456
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
456
01:29Inflammatory Bowel Disease IV: Pharmacological Management
517
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
517